Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Intellia Therapeutics has raised $180.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Intellia Therapeutics's investors include Novartis, OrbiMed, Foresite Capital, Fidelity, EcoR1 Capital.
Intellia Therapeutics is headquartered in Cambridge, United States.
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Intellia Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Intellia Therapeutics — Funding & Investors." VCBacked, April 29, 2026, https://www.vcbacked.co/company/intellia-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Intellia Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/intellia-therapeutics
{{cite web |title=Intellia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/intellia-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated